[Can we still afford progress in intensive care medicine? Re: the article from DMW 1-2/2004].
Jörg
J
Rustige
D018806:APACHE; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003422:Critical Care / Q000191:economics* / Q000639:trends; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D009102:Multiple Organ Failure / Q000150:complications / Q000401:mortality; D011486:Protein C / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D018805:Sepsis / Q000150:complications / Q000188:drug therapy* / Q000401:mortality
D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated